Literature DB >> 34515804

Decreased Serum Level of Interleukin-22 Correlates with Hepcidin in Patients with Hidradenitis Suppurativa.

Malgorzata Ponikowska1, Łukasz Matusiak, Monika Kasztura, Ewa Jankowska, Jacek C Szepietowski.   

Abstract

Current understanding of the underlying pathophysiology of hidradenitis suppurativa (HS) links the disease with proinflammatory activation and autoimmune processes. This study investigated serum levels of interleukin (IL)-22, a cytokine critically involved in epithelial homeostasis, in the context of the broad clinical spectrum of patients with HS. The study also assessed the relationship between serum IL-22 and pro-inflammatory activation (as evidenced by serum level of IL-6) and serum hepcidin (central regulator of systemic iron homeostasis). Serum concentrations of IL-22 were assessed in 74 patients with HS and 15 healthy subjects. Compared with healthy controls, patients with HS demonstrated decreased levels of serum IL-22 (median; interquartile range (IQR): 12.4 pg/ml (9.8; 23.5) vs 34.8 pg/ml (24.8; 39.8), p < 0.001 vs controls). Disease severity (assessed both with Hurley staging and Hidradenitis Suppurativa Severity Index) did not differentiate IL-22 levels (p > 0.1 in both comparisons). Serum levels of IL-22 and IL-6 did not correlate with each other (R=-0.17, p = ns). In a subgroup of 24 patients with HS with pro-inflammatory activation, the mean level of IL-22 was similar to that of the remaining patients (median (IQR): 9.8 pg/ml (8.5; 15.0) vs 12.0 pg/ml (9.4; 16.3), p = ns). Patients with HS demonstrated a decreased level of hepcidin (mean: 31.3 ± 25.9 pg/ml), which correlated with the levels of IL-22 (R=0.36, p <0.05). Patients with HS demonstrated significantly decreased levels of serum IL-22, which was neither correlated with pro-inflammatory status nor associated with disease severity, but correlated modestly with serum hepcidin.

Entities:  

Keywords:  cytokines; hepcidin; interleukin-22; hidradenitis suppurativa

Mesh:

Substances:

Year:  2021        PMID: 34515804      PMCID: PMC9425619          DOI: 10.2340/00015555-3928

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  27 in total

Review 1.  Pathophysiology of hidradenitis suppurativa: An update.

Authors:  Errol Prens; Inge Deckers
Journal:  J Am Acad Dermatol       Date:  2015-11       Impact factor: 11.527

2.  Severe hidradenitis suppurativa successfully treated with secukinumab.

Authors:  Amelia Głowaczewska; Jacek C Szepietowski; Łukasz Matusiak
Journal:  Dermatol Ther       Date:  2020-07-05       Impact factor: 2.851

3.  IL-22 regulates iron availability in vivo through the induction of hepcidin.

Authors:  Carole L Smith; Tara L Arvedson; Keegan S Cooke; Leslie J Dickmann; Carla Forte; Hongyan Li; Kimberly L Merriam; V Kristina Perry; Linh Tran; James B Rottman; Joseph R Maxwell
Journal:  J Immunol       Date:  2013-07-08       Impact factor: 5.422

4.  Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial.

Authors:  Annika Grant; Tayler Gonzalez; Michael O Montgomery; Vanessa Cardenas; Francisco A Kerdel
Journal:  J Am Acad Dermatol       Date:  2010-02       Impact factor: 11.527

5.  Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.

Authors:  H H van der Zee; L de Ruiter; D G van den Broecke; W A Dik; J D Laman; E P Prens
Journal:  Br J Dermatol       Date:  2011-05-17       Impact factor: 9.302

6.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.

Authors:  C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-01-30       Impact factor: 6.166

7.  Inherent differences in keratinocyte function in hidradenitis suppurativa: Evidence for the role of IL-22 in disease pathogenesis.

Authors:  Derek Jones; Anirban Banerjee; Peter Z Berger; Alexandra Gross; Sean McNish; Richard Amdur; Victoria K Shanmugam
Journal:  Immunol Invest       Date:  2017-10-03       Impact factor: 3.657

Review 8.  IL-6 in inflammation, immunity, and disease.

Authors:  Toshio Tanaka; Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-09-04       Impact factor: 10.005

Review 9.  Therapeutic opportunities of the IL-22-IL-22R1 system.

Authors:  Robert Sabat; Wenjun Ouyang; Kerstin Wolk
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

10.  Acne inversa: evaluating antimicrobial peptides and proteins.

Authors:  Falk G Bechara; Michael Sand; Marina Skrygan; Alexander Kreuter; Peter Altmeyer; Thilo Gambichler
Journal:  Ann Dermatol       Date:  2012-11-08       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.